Denmark Raises GDP Forecast to 3.7% on Novo Nordisk Exports While Shares Slide 43%
NVO•Danske Bank raised 2026 Denmark GDP forecast to 3.7% from 3.0% as export volumes swell on rising demand for Novo Nordisk products, while its shares have fallen 43% over the past year. US obesity-market pricing pressure is intensifying, though Novo’s deep GLP-1 pipeline may drive a rebound.
1. Export-Led GDP Upgrade Drives Growth Expectations
Danske Bank raised its 2026 GDP forecast for Denmark to 3.7% from 3.0%, citing strong export momentum tied to demand for Novo Nordisk’s diabetes and obesity products. This upgrade places Denmark above the 2.3% European median and highlights Novo Nordisk as a key driver of national export growth.
2. Stock Performance and Pricing Pressure
Over the past twelve months, Novo Nordisk shares have declined approximately 43% as competition in the US obesity market intensifies. While export volumes remain robust, margin compression from pricing concessions in the US has weighed on the company’s overall profitability metrics.
3. GLP-1 Pipeline Offers Rebound Potential
Novo Nordisk’s pipeline features next-generation GLP-1 candidates in late-stage trials targeting cardiovascular and weight-loss indications. These assets are viewed by analysts as potential catalysts that could restore growth momentum and support valuation in upcoming quarters.
